COVID-19 patients who experience cytokine storms may make few memory B cells

19-Aug-2020 10:50 AM EDT, by Cell Press

Newswise — The release of massive amounts of proteins called cytokines can lead to some of the most severe symptoms of COVID-19. When large numbers of immune cells release cytokines, this increases inflammation and creates a feedback loop in which more immune cells are activated and this is sometimes called a cytokine storm. An August 19 study in the journal Cell now suggests that high levels of some cytokines may also prevent people who are infected from developing long-term immunity as affected patients were observed to make very few of the type of B cells needed to develop a durable immune response.

"We've seen a lot of studies suggesting that immunity to COVID-19 is not durable because the antibodies decline over time," says co-senior author Shiv Pillai, a professor at Harvard Medical School and member of the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard. "This study provides a mechanism that explains this lower-quality immune response."

The investigators focused on germinal centers--the areas within the lymph nodes and spleens where B cells, the immune cells that produce antibodies, differentiate. Differentiation and changes in antibody genes are required to build immunity to an infectious agent.

"When we looked at the lymph nodes and spleens of patients who died from COVID-19, including some who died very soon after getting the disease, we saw that these germinal center structures had not formed," says co-senior author Robert Padera, a pathology professor at Harvard. "We decided to determine why that's the case."

Because the disease was so new, animal models for studying COVID-19 infection were not yet available at the time they began their study. The researchers instead gained insights from previous studies involving mouse models of other infections that induce cytokine storm syndrome--a malaria model and one of bacterial infection in which germinal centers were lost.

In people with severe COVID-19, one of most abundant cytokines released is called TNF. In the infected mice, TNF appeared to block the formation of germinal centers. In previous cytokine storm models, when the mice were given antibodies to block TNF or had their TNF gene deleted, the germinal centers were able to form. When the researchers studied the lymph nodes of patients who had died of the disease, they found high levels of TNF in these organs. This led them to conclude that TNF may be preventing the germinal centers from forming in people with COVID-19 as well.

"Studies have suggested this lack of germinal centers happens with SARS infections," Pillai says. "We even think this phenomenon occurs in some patients with Ebola, so it was not surprising to us."

The researchers also studied blood and lymphoid tissue from people with active infections who were in different stages of COVID-19. They found that although germinal centers were not formed, B cells were still activated and appeared in the blood, which would allow the patients to produce some neutralizing antibodies. "There is an immune response," Padera says. "It's just not coming from a germinal center."

"Without the germinal centers, there is no long-term memory to the antigens," Pillai adds. He notes that studies of other coronaviruses that cause colds have suggested that someone can get infected with the same coronavirus three or four times in the same year.

The authors say despite their findings, they still believe a successful COVID-19 vaccine can be developed as it should not cause high levels of cytokines to be released.

###

This work was supported by the National Institutes of Health and the National Institute of General Medical Sciences. Funding for these studies from the Massachusetts Consortium of Pathogen Readiness, the Mark and Lisa Schwartz Foundation and Enid Schwartz is also acknowledged.

Cell, Kaneko, Kuo, Boucau, Farmer et al.: "The loss of Bcl-6 expressing T follicular helper cells and the absence of germinal centers in COVID-19" https://www.cell.com/cell/fulltext/S0092-8674(20)31067-9

Cell (@CellCellPress), the flagship journal of Cell Press, is a bimonthly journal that publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Visit: http://www.cell.com/cell. To receive Cell Press media alerts, contact press@cell.com.

SEE ORIGINAL STUDY




Filters close

Showing results

1120 of 4204
access_time Embargo lifts in 2 days
Embargo will expire: 10-Dec-2020 12:00 PM EST Released to reporters: 3-Dec-2020 1:50 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 10-Dec-2020 12:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Chicago neighborhoods with barriers to social distancing had higher COVID-19 death rates
Released: 3-Dec-2020 11:55 AM EST
Chicago neighborhoods with barriers to social distancing had higher COVID-19 death rates
University of Illinois at Chicago

New research has found that Chicago neighborhoods with barriers to social distancing, including limited access to broadband internet and low rates of health insurance, had more COVID-19 deaths in spring 2020. The study, led by researchers at the University of Illinois Chicago, is published in the Annals of Epidemiology.

Released: 3-Dec-2020 9:45 AM EST
Nearly Half of Community Health Center Patients Qualify for Phase One COVID-19 Vaccinations
George Washington University

Nearly half of all patients served by community health centers (CHCs) qualify for phase one COVID-19 immunizations under priority guidelines established by the Centers for Disease Control and Prevention, according to a new analysis produced by researchers at the Geiger Gibson/RCHN Community Health Foundation Research Collaborative.

Released: 3-Dec-2020 9:00 AM EST
Sociologists Available to Discuss Vaccines and COVID-19
American Sociological Association (ASA)

As coronavirus cases rage throughout the United States—killing more than a quarter million in the U.S.—news of the effectiveness of vaccine candidates provides hope.

access_time Embargo lifts in 2 days
Embargo will expire: 8-Dec-2020 11:00 AM EST Released to reporters: 3-Dec-2020 8:30 AM EST

A reporter's PressPass is required to access this story until the embargo expires on 8-Dec-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: The Medical Minute: Helping young athletes return to play safely after COVID-19
Released: 3-Dec-2020 8:20 AM EST
The Medical Minute: Helping young athletes return to play safely after COVID-19
Penn State Health

Young athletes in central Pennsylvania can’t wait to start basketball and wrestling season. But with the COVID-19 pandemic raging, parents wonder how their children can stay safe. And, if their child gets COVID-19, parents wonder when it’s safe for that child to get back to competitive sports.

Released: 2-Dec-2020 6:05 PM EST
How Caregivers of People with Dementia Can Navigate Holidays During the Pandemic
Rutgers University-New Brunswick

As COVID-19 cases increase across the nation, many caregivers are trying to navigate the holidays for relatives with dementia or Alzheimer’s disease. The Centers for Disease Control and Prevention suggests that people not travel to limit the potential spread of the coronavirus. Mary Catherine Lundquist, program director of Care2Caregivers, a peer counseling helpline (800-424-2494) for caregivers of people with dementia and Alzheimer’s disease operated by Rutgers Behavioral Health Care, discusses how families can stay connected with their loved ones.

Released: 2-Dec-2020 3:50 PM EST
Tip Sheet: Celebrate holidays safely, COVID-19 vaccines, challenges in HIV vaccine trials — and new insights on evolution
Fred Hutchinson Cancer Research Center

SEATTLE – Dec. 2, 2020 – Below are summaries of recent Fred Hutch research findings and other news with links for additional background and media contacts.If you’re following the American Society of Hematology’s annual meeting (virtual, Dec. 5-8), see our media tip sheet highlighting Fred Hutch presentations and activities, including those by current ASH president Dr.

Newswise: “This is how we can help” – Couple shares their story as COVID-19 clinical trial participants
Released: 2-Dec-2020 2:35 PM EST
“This is how we can help” – Couple shares their story as COVID-19 clinical trial participants
University of Texas Health Science Center at Houston

“I don’t feel so great,” my husband, Brandon, said to me one Saturday afternoon – the last thing I wanted to hear after spending the last seven months tuned into COVID-19 media coverage. Knowing a few of his co-workers had recently tested positive for the virus, we didn’t wait to secure an appointment for a rapid test. When he called me an hour later to tell me he has tested positive, my heart sank.


Showing results

1120 of 4204

close
0.93594